Top Stories
Etcamah (camizestrant) was granted an accelerated approval even though the agency's advisory panel voted against the drug's biomarker-driven switching strategy.
The biotech wants to take a selective M4 drug called NS-136 into Phase II schizophrenia and Alzheimer's agitation trials, and advance two other candidates as well.
As the companies eye an FDA filing next year, long-term extension data from Phase I/IIa studies point to sustained seizure control and neurodevelopmental gains.
In March, Pfizer had terminated a Phase I trial of PF-08046031, an antibody-drug conjugate (ADC), in patients with melanoma and other solid tumours.
Zanvastro (zilganersen), an antisense oligonucleotide, is the first therapy shown to stop production and accumulation of excess GFAP in patients with the rare neurological disease.
Conference News
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and ...
Largest randomized individual patient-data analysis to date evaluating 1- versus 12-month dual antiplatelet therapy exclusively in patients with acute myocardial infarction (3,966 patients) Major blee...
SHANGHAI, Sept. 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical result...
- Oral Presentation in Session VI: Hereditary AngioedemaSHANGHAI and NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (...
ESC gets to the heart of key drug battles in cardiologyThe European Society of Cardiology (ESC) annual meeting provided lots of answers, and arguably, even more questions. The failed CARDIO-TTRansform...
